Vaccine Therapy in Preventing Cervical Cancer in Patients With Cervical Intraepithelial Neoplasia
Recruitment status was Active, not recruiting
RATIONALE: Vaccines made from protein and DNA may help the body build an effective immune response to kill abnormal cells in the cervix. The use of vaccine therapy may prevent cervical cancer.
PURPOSE: This phase I/II trial is studying the side effects and best dose of vaccine therapy and to see how well it works in preventing cervical cancer in patients with cervical intraepithelial neoplasia and human papillomavirus.
Biological: pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine
|Study Design:||Primary Purpose: Prevention|
|Official Title:||A Phase I/II Clinical Trial of pNGVL4a-Sig/E7 (Detox)/HSP70 for the Treatment of Patients With HPV 16+ Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)|
- Toxicity [ Designated as safety issue: Yes ]
- Efficacy [ Designated as safety issue: No ]
- Changes in lesion size and human papillomavirus viral load [ Designated as safety issue: No ]
- Cellular, humoral, and local tissue immune responses [ Designated as safety issue: No ]
- Correlate measures of immune response with clinical response [ Designated as safety issue: No ]
- Correlate measures of immune response with the preclinical model [ Designated as safety issue: No ]
|Study Start Date:||November 2003|
|Estimated Primary Completion Date:||April 2009 (Final data collection date for primary outcome measure)|
- Determine the feasibility and toxicity of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine in preventing cervical cancer in patients with human papillomavirus (HPV)-16-positive grade 2 or 3 cervical intraepithelial neoplasia.
- Determine the effect of this vaccine on the histology of cervical tissue specimens from these patients.
- Determine changes in lesion size and HPV viral load in patients treated with this vaccine.
- Determine the cellular, humoral, and local tissue immune responses in patients treated with this vaccine.
- Correlate measures of immune response with clinical response in patients treated with this vaccine.
- Correlate measures of immune response in patients treated with this vaccine with those observed in the preclinical model.
OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.
- Phase I: Patients receive pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine subcutaneously once in weeks 0, 4, and 8 in the absence of disease progression or unacceptable toxicity. Patients undergo colposcopy in week 8, 15 and 19 and a therapeutic loop electrosurgical excision procedure (LEEP) in week 15.
Cohorts of patients receive escalating doses of vaccine until the safest dose is determined.
- Phase II: Patients receive vaccine as in phase I but at the safest dose determined in phase I. Patients also undergo colposcopy and LEEP as in phase I.
After completion of the study treatment, patients are followed annually for 15 years.
PROJECTED ACCRUAL: Approximately 150 patients (approximately 12 will be treated in phase I and 25 will be treated in phase II) will be accrued for this study.
|United States, Maryland|
|Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|
|Baltimore, Maryland, United States, 21231-2410|
|Study Chair:||Cornelia L. Trimble, MD||Sidney Kimmel Comprehensive Cancer Center|